Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen people search for tirzepatide face before and after results, they are usually asking whether the weight loss shows in the face first, how dramatic the change is, and whether it looks natural. The honest answer: facial changes are among the earliest visible signs, typically appearing within the first one to three months, and they can be striking — but the picture is more nuanced than a side-by-side photo suggests. Tirzepatide is a prescription-only medicine; a clinician decides whether it is appropriate for you, and results differ from person to person. What follows is a plain account of what the evidence and clinical experience tell us.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The face is not where most of the body's fat is stored, which is precisely why changes there are visible so quickly. As tirzepatide reduces appetite through its dual GIP and GLP-1 receptor action, total caloric intake falls, and the body draws on fat stores across the whole frame, but small reductions in subcutaneous facial fat produce a proportionally large visual effect. The cheeks may appear less rounded. The jaw can become more defined. The area under the eyes sometimes looks slightly less puffy.
This can begin earlier than most people expect. Some people notice a change in their face within the first month, before the bathroom scales have moved dramatically. The full timeline of how tirzepatide takes effect depends on dose, adherence and individual metabolism, but the face is often the mirror that catches progress first.
According to the NHS's information on tirzepatide, the medicine works by slowing how quickly the stomach empties and signalling fullness to the brain; the downstream consequence is sustained, meaningful weight loss that (unlike crash dieting) tends to be more evenly distributed across the body over time.
Photos circulating online vary enormously in quality, lighting and framing. Some are genuine; a significant number are not. The MHRA has warned publicly about counterfeit GLP-1 pens sold through social media channels, and unofficial communities promoting these images sometimes blur the line between real treatment results and promotional material. That is worth bearing in mind before any image shapes your expectations.
What genuine facial change looks like in practice tends to be progressive rather than dramatic. At the one-month mark, most people are still on the 2.5mg starter dose, which is designed to help the body adjust rather than produce the full effect. Visible facial change at that stage is possible but modest. By months three to six, especially after dose increases, the shift tends to become more pronounced. The changes that appear in men and in women can differ, men's results often show more pronounced jaw and neck definition.
One thing photos rarely convey is skin response. Facial skin has more elasticity than abdominal skin, which is generally good news, but the pace of loss matters. Rapid early loss can occasionally produce a slightly deflated look around the cheeks and temples. Slower, sustained loss (more typical of the titration schedule on tirzepatide) tends to allow skin time to adapt.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, found average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks in adults with obesity. Changes on that scale will alter most people's faces noticeably. But that figure is a trial average, results depend heavily on which dose you reach, how long you stay on treatment, what you eat, and your baseline body composition.
Facial fat distribution is also partly genetic. Some people carry most of their excess weight in the face and neck; others carry very little there. If you are in the latter group, dramatic facial change is less likely even with significant total weight loss. This is not a failure of the medicine; it reflects normal variation in fat distribution.
For a practical sense of costs involved in starting treatment, the Mounjaro pricing page sets out what private treatment involves. The question of whether tirzepatide is the right medicine for your specific situation (including your weight, health history and goals) is one that a prescriber works through at consultation. It is not a decision a photo can make.
The shape of your facial change is influenced by how treatment is managed. Dose titration, aftercare support when side effects slow your eating, and guidance on adequate protein intake during weight loss all affect whether the result looks healthy rather than gaunt. These are not cosmetic fine points; they are part of safe, supervised treatment.
At nume, a GPhC-registered Independent Prescriber personally reviews every consultation (the same day) before any prescription is issued. Nothing is automated. Your pen arrives via DPD the next working day in plain, unmarked packaging, and prescribers are available seven days a week if questions come up after you start. You can read more about how the service is structured on the about us page.
The broader picture of what tirzepatide results look like over time (not just the face) is covered in detail on the tirzepatide before and after results page. For those specifically curious about changes after the first four weeks, the one-month facial changes page goes into more detail. And if you want to see how this compares with the broader Mounjaro results picture, the Mounjaro face before and after page covers that ground. These are prescription-only medicines, and any decision to start them belongs to a clinician, not a comparison gallery. If you are ready to find out whether you are clinically suitable, start your free consultation and a prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.